On September 15, 2022 Ariceum Therapeutics (Ariceum), a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, reported that its senior management team will be attending and hosting meetings at the following investor and scientific conferences in the fourth quarter of 2022 (Press release, Ariceum Therapeutics, SEP 15, 2022, View Source [SID1234619569])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Terachem 2022: The Fourth International Symposium on Technetium and Other Radiometals in Chemistry and Medicine
14-17 September 2022, Forum Brixen, Bressanone, Italy

9th Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Conference (ITOC)
22-24 September 2022, Klinikum der Universität München, Munich, Germany

Optimum 14th Annual Healthcare Investor Conference
6 October 2022, Wellcome Collection, London, UK

European Association of Nuclear Medicine (EANM) 35th Annual Congress
15-19 October 2022, Barcelona International Convention Centre, Barcelona, Spain

BIO-Europe 2022
24-26 October 2022, Leipzig Messe, Leipzig, Germany

4th Targeted Radiopharmaceuticals EU Summit Europe
6-8 December 2022, Leonard Royal, Amsterdam, Netherlands

Presentation by: Chief Executive Officer, Manfred Rüdiger, Ariceum Therapeutics
Title: New Life for Satoreotide-The Antagonist Moves
Date & Time: 6 December, 12.00pm CET

European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Immuno-Oncology Annual Congress
7-9 December 2022, Palexpo exhibition centre, Geneva, Switzerland